BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons

Molecular and Cellular Neuroscience

Volumn 56, Issue , 2013, Pages 263-271

  Hegarty, Shane V ^a   Sullivan, Aideen M ^a   O'Keeffe, Gerard W ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

BMP receptor; BMP2; Dorsomorphin; GDF5; Neuronal differentiation; SH SY5Y cells; Smad signalling

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; GROWTH DIFFERENTIATION FACTOR 5; NEUROTROPHIC FACTOR; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN;

ARTICLE; CELL FUNCTION; CELL LINE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MESENCEPHALON; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

BMP RECEPTOR; BMP(S); BMP2; BMPR(S); BONE MORPHOGENETIC PROTEIN RECEPTOR(S); BONE MORPHOGENETIC PROTEIN(S); CABMPRIB; CONSTITUTIVELY ACTIVE BMPRIB; DA; DAY(S) IN VITRO; DIV; DOPAMINERGIC/DOPAMINE; DORSOMORPHIN; GDF(S); GDF5; GDNF; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GROWTH DIFFERENTIATION FACTOR(S); MAPK; MITOGEN ACTIVATED PROTEIN KINASES; MTT; N; NEURONAL DIFFERENTIATION; NUMBER OF REPETITIONS; PBS; PHOSPHATE BUFFERED SALINE; REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; RT-PCR; SH-SY5Y CELLS; SMAD 1/5/8; SMAD SIGNALLING; SMAD1, SMAD5 AND SMAD8; TGF; THIAZOLYL BLUE TETRAZOLIUM BROMIDE; TRANSFORMING GROWTH FACTOR; VENTRAL MIDBRAIN; VM;

BONE MORPHOGENETIC PROTEIN 2; CELL LINE, TUMOR; DOPAMINERGIC NEURONS; GROWTH DIFFERENTIATION FACTOR 5; HUMANS; MESENCEPHALON; NEUROGENESIS; RECOMBINANT PROTEINS; SMAD PROTEINS;

EID: 84880931569     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2013.06.006     Document Type: Article

References (64)

1. Bonnamain V., Neveu I., Naveilhan P. Neural stem/progenitor cells as a promising candidate for regenerative therapy of the central nervous system. Front. Cell. Neurosci. 2012, 6:17.
2. Chizhikov V.V., Millen K.J. Roof plate-dependent patterning of the vertebrate dorsal central nervous system. Dev. Biol. 2005, 277:287-295.
3. Collins L.M., O'Keeffe G.W., Long-Smith C.M., Wyatt S.L., Sullivan A.M., Toulouse A., Nolan Y.M. Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons. Neuromolecular Med. 2013, 15:435-446.
4. Costello D.J., O'Keeffe G.W., Hurley F.M., Sullivan A.M. Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease. J. Cell. Mol. Med. 2012, 16:2451-2460.
5. David L., Mallet C., Mazerbourg S., Feige J.J., Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
6. De Feo D., Merlini A., Laterza C., Martino G. Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. Curr. Opin. Neurol. 2012, 25:322-333.
7. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
8. Drevelle O., Daviau A., Lauzon M.A., Faucheux N. Effect of BMP-2 and/or BMP-9 on preosteoblasts attached to polycaprolactone functionalized by adhesive peptides derived from bone sialoprotein. Biomaterials 2013, 34:1051-1062.
9. Eivers E., Fuentealba L.C., De Robertis E.M. Integrating positional information at the level of Smad1/5/8. Curr. Opin. Genet. Dev. 2008, 18:304-310.
10. Espejo M., Cutillas B., Ventura F., Ambrosio S. Exposure of foetal mesencephalic cells to bone morphogenetic protein-2 enhances the survival of dopaminergic neurones in rat striatal grafts. Neurosci. Lett. 1999, 275:13-16.
11. Fuentealba L.C., Eivers E., Ikeda A., Hurtado C., Kuroda H., Pera E.M., De Robertis E.M. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 2007, 131:980-993.
12. Gilboa L., Nohe A., Geissendorfer T., Sebald W., Henis Y.I., Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol. Biol. Cell 2000, 11:1023-1035.
13. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
14. Gomez-Santos C., Ambrosio S., Ventura F., Ferrer I., Reiriz J. TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells. Brain Res. 2002, 958:152-160.
15. Gratacos E., Checa N., Perez-Navarro E., Alberch J. Brain-derived neurotrophic factor (BDNF) mediates bone morphogenetic protein-2 (BMP-2) effects on cultured striatal neurones. J. Neurochem. 2001, 79:747-755.
16. Gromova K.V., Friedrich M., Noskov A., Harms G.S. Visualizing Smad1/4 signaling response to bone morphogenetic protein-4 activation by FRET biosensors. Biochim. Biophys. Acta 2007, 1773:1759-1773.
17. Hazen V.M., Phan K.D., Hudiburgh S., Butler S.J. Inhibitory Smads differentially regulate cell fate specification and axon dynamics in the dorsal spinal cord. Dev. Biol. 2011, 356:566-575.
18. Hazen V.M., Andrews M.G., Umans L., Crenshaw E.B., Zwijsen A., Butler S.J. BMP receptor-activated Smads confer diverse functions during the development of the dorsal spinal cord. Dev. Biol. 2012, 367:216-227.
19. Hedlund E., Perlmann T. Neuronal cell replacement in Parkinson's disease. J. Intern. Med. 2009, 266:358-371.
20. Hurley F.M., Costello D.J., Sullivan A.M. Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Exp. Neurol. 2004, 185:281-289.
21. Iwasaki S., Hattori A., Sato M., Tsujimoto M., Kohno M. Characterization of the bone morphogenetic protein-2 as a neurotrophic factor. Induction of neuronal differentiation of PC12 cells in the absence of mitogen-activated protein kinase activation. J. Biol. Chem. 1996, 271:17360-17365.
22. Iwasaki S., Iguchi M., Watanabe K., Hoshino R., Tsujimoto M., Kohno M. Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J. Biol. Chem. 1999, 274:26503-26510.
23. Jordan J., Bottner M., Schluesener H.J., Unsicker K., Krieglstein K. Bone morphogenetic proteins: neurotrophic roles for midbrain dopaminergic neurons and implications of astroglial cells. Eur. J. Neurosci. 1997, 9:1699-1709.
24. Krieglstein K., Suter-Crazzolara C., Hötten G., Pohl J., Unsicker K. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J. Neurosci. Res. 1995, 42:724-732.
25. Kudo T.A., Kanetaka H., Mizuno K., Ryu Y., Miyamoto Y., Nunome S., Zhang Y., Kano M., Shimizu Y., Hayashi H. Dorsomorphin stimulates neurite outgrowth in PC12 cells via activation of a protein kinase A-dependent MEK-ERK1/2 signaling pathway. Genes Cells 2011, 16:1121-1132.
26. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
27. Lee K.J., Jessell T.M. The specification of dorsal cell fates in the vertebrate central nervous system. Annu. Rev. Neurosci. 1999, 22:261-294.
28. Lee K.J., Mendelsohn M., Jessell T.M. Neuronal patterning by BMPs: a requirement for GDF7 in the generation of a discrete class of commissural interneurons in the mouse spinal cord. Genes Dev. 1998, 12:3394-3407.
29. Liem K.F., Tremml G., Roelink H., Jessell T.M. Dorsal differentiation of neural plate cells induced by BMP-mediated signals from epidermal ectoderm. Cell 1995, 82:969-979.
30. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
31. Liu A., Niswander L.A. Bone morphogenetic protein signalling and vertebrate nervous system development. Nat. Rev. Neurosci. 2005, 6:945-954.
32. Mayhew T.M. A review of recent advances in stereology for quantifying neural structure. J. Neurocytol. 1992, 21:313-328.
33. McMillan C.R., Sharma R., Ottenhof T., Niles L.P. Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci. Lett. 2007, 419:202-206.
34. Miyazono K., Kusanagi K., Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J. Cell. Physiol. 2001, 187:265-276.
35. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147:35-51.
36. Monteiro R.M., de Sousa Lopes S.M., Bialecka M., de Boer S., Zwijsen A., Mummery C.L. Real time monitoring of BMP Smads transcriptional activity during mouse development. Genesis 2008, 46:335-346.
37. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J. Cell Sci. 2005, 118:3573-3584.
38. Nakamura S., Ito Y., Shirasaki R., Murakami F. Local directional cues control growth polarity of dopaminergic axons along the rostrocaudal axis. J. Neurosci. 2000, 20:4112-4119.
39. Nakamura Y., Ozaki T., Koseki H., Nakagawara A., Sakiyama S. Accumulation of p27 KIP1 is associated with BMP2-induced growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines. Biochem. Biophys. Res. Commun. 2003, 307:206-213.
40. Niere M., Braun B., Gass R., Sturany S., Volkmer H. Combination of engineered neural cell adhesion molecules and GDF-5 for improved neurite extension in nerve guide concepts. Biomaterials 2006, 27:3432-3440.
41. Nishitoh H., Ichijo H., Kimura M., Matsumoto T., Makishima F., Yamaguchi A., Yamashita H., Enomoto S., Miyazono K. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J. Biol. Chem. 1996, 271:21345-21352.
42. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I., Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 2002, 277:5330-5338.
43. O'Keeffe G.W., Dockery P., Sullivan A.M. Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro. J. Neurocytol. 2004, 33:479-488.
44. O'Keeffe G.W., Hanke M., Pohl J., Sullivan A.M. Expression of growth differentiation factor-5 in the developing and adult rat brain. Brain Res. Dev. Brain Res. 2004, 151:199-202.
45. Orlacchio A., Bernardi G., Martino S. Stem cells and neurological diseases. Discov. Med. 2010, 9:546-553.
46. Parikh P., Hao Y., Hosseinkhani M., Patil S.B., Huntley G.W., Tessier-Lavigne M., Zou H. Regeneration of axons in injured spinal cord by activation of bone morphogenetic protein/Smad1 signaling pathway in adult neurons. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E99-E107.
47. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005, 57:298-302.
48. Phan K.D., Hazen V.M., Frendo M., Jia Z., Butler S.J. The bone morphogenetic protein roof plate chemorepellent regulates the rate of commissural axonal growth. J. Neurosci. 2010, 30:15430-15440.
49. Presgraves S.P., Ahmed T., Borwege S., Joyce J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 2004, 5:579-598.
50. Reiriz J., Espejo M., Ventura F., Ambrosio S., Alberch J. Bone morphogenetic protein-2 promotes dissociated effects on the number and differentiation of cultured ventral mesencephalic dopaminergic neurons. J. Neurobiol. 1999, 38:161-170.
51. Sieber C., Kopf J., Hiepen C., Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009, 20:343-355.
52. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
53. Sullivan A.M., O'Keeffe G.W. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment. J. Anat. 2005, 207:219-226.
54. Sullivan A.M., Toulouse A. Neurotrophic factors for the treatment of Parkinson's disease. Cytokine Growth Factor Rev. 2011, 22:157-165.
55. Sullivan A.M., Opacka-Juffry J., Hotten G., Pohl J., Blunt S.B. Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neurosci. Lett. 1997, 233:73-76.
56. Sullivan A.M., Pohl J., Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur. J. Neurosci. 1998, 10:3681-3688.
57. Sullivan A.M., Opacka-Juffry J., Pohl J., Blunt S.B. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res. 1999, 818:176-179.
58. Toulouse A., Sullivan A.M. Progress in Parkinson's disease-where do we stand?. Prog. Neurobiol. 2008, 85:376-392.
59. Toulouse A., Collins G.C., Sullivan A.M. Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line. Neurotox. Res. 2012, 21:256-265.
60. Ulloa F., Briscoe J. Morphogens and the control of cell proliferation and patterning in the spinal cord. Cell Cycle 2007, 6:2640-2649.
61. Wood T.K., McDermott K.W., Sullivan A.M. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J. Neurosci. Res. 2005, 80:759-766.
62. Xiao Y.T., Xiang L.X., Shao J.Z. Bone morphogenetic protein. Biochem. Biophys. Res. Commun. 2007, 362:550-553.
63. Xie H.R., Hu L.S., Li G.Y. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin. Med. J. (Engl) 2010, 123:1086-1092.
64. Yu P.B., Hong C.C., Sachidanandan C., Babitt J.L., Deng D.Y., Hoyng S.A., Lin H.Y., Bloch K.D., Peterson R.T. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 2008, 4:33-41.